Ignite Creation Date:
2025-12-24 @ 6:59 PM
Ignite Modification Date:
2026-05-13 @ 3:05 PM
Study NCT ID:
NCT06590857
Status:
RECRUITING
Last Update Posted:
2025-08-12
First Post:
2024-09-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Sponsor:
RayzeBio, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
RYZ101-201
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None